Similar articles for PMID: 30347088

Year	Number of Results
1967	2
1980	1
1982	1
1991	2
1992	1
1993	2
1995	1
1997	2
1998	3
1999	4
2000	2
2001	5
2002	4
2003	3
2004	1
2005	4
2006	6
2007	5
2008	9
2009	4
2010	3
2011	10
2012	2
2013	7
2014	12
2015	5
2016	4
2017	5
2018	5
2019	10
2020	9
2021	12
2022	8
2023	6
2024	1

1

Minimal Efficacy of Nitisinone Treatment in a Novel Mouse Model of Oculocutaneous Albinism, Type 3.

Onojafe IF, Megan LH, Melch MG, Aderemi JO, Alur RP, Abu-Asab MS, Chan CC, Bernardini IM, Albert JS, Cogliati T, Adams DR, Brooks BP. Onojafe IF, et al. Invest Ophthalmol Vis Sci. 2018 Oct 1;59(12):4945-4952. doi: 10.1167/iovs.16-20293. Invest Ophthalmol Vis Sci. 2018. PMID: 30347088 Free PMC article.

2

Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism.

Onojafe IF, Adams DR, Simeonov DR, Zhang J, Chan CC, Bernardini IM, Sergeev YV, Dolinska MB, Alur RP, Brilliant MH, Gahl WA, Brooks BP. Onojafe IF, et al. J Clin Invest. 2011 Oct;121(10):3914-23. doi: 10.1172/JCI59372. J Clin Invest. 2011. PMID: 21968110 Free PMC article.

3

Informed reasoning: repositioning of nitisinone to treat oculocutaneous albinism.

Manga P, Orlow SJ. Manga P, et al. J Clin Invest. 2011 Oct;121(10):3828-31. doi: 10.1172/JCI59763. J Clin Invest. 2011. PMID: 21968107 Free PMC article.

4

Tyrp1 and oculocutaneous albinism type 3.

Sarangarajan R, Boissy RE. Sarangarajan R, et al. Pigment Cell Res. 2001 Dec;14(6):437-44. doi: 10.1034/j.1600-0749.2001.140603.x. Pigment Cell Res. 2001. PMID: 11775055 Review.

5

Molecular characterization of SLC24A5 variants and evaluation of Nitisinone treatment efficacy in a zebrafish model of OCA6.

Yousaf S, Sethna S, Chaudhary MA, Shaikh RS, Riazuddin S, Ahmed ZM. Yousaf S, et al. Pigment Cell Melanoma Res. 2020 Jul;33(4):556-565. doi: 10.1111/pcmr.12879. Epub 2020 Apr 27. Pigment Cell Melanoma Res. 2020. PMID: 32274888 Free PMC article.

6

Tyrosinase processing and intracellular trafficking is disrupted in mouse primary melanocytes carrying the underwhite (uw) mutation. A model for oculocutaneous albinism (OCA) type 4.

Costin GE, Valencia JC, Vieira WD, Lamoreux ML, Hearing VJ. Costin GE, et al. J Cell Sci. 2003 Aug 1;116(Pt 15):3203-12. doi: 10.1242/jcs.00598. J Cell Sci. 2003. PMID: 12829739

7

Oculocutaneous albinism types 1 and 3 are ER retention diseases: mutation of tyrosinase or Tyrp1 can affect the processing of both mutant and wild-type proteins.

Toyofuku K, Wada I, Valencia JC, Kushimoto T, Ferrans VJ, Hearing VJ. Toyofuku K, et al. FASEB J. 2001 Oct;15(12):2149-61. doi: 10.1096/fj.01-0216com. FASEB J. 2001. PMID: 11641241

8

Oculocutaneous albinism type 3: a Japanese girl with novel mutations in TYRP1 gene.

Yamada M, Sakai K, Hayashi M, Hozumi Y, Abe Y, Kawaguchi M, Ihn H, Suzuki T. Yamada M, et al. J Dermatol Sci. 2011 Dec;64(3):217-22. doi: 10.1016/j.jdermsci.2011.09.005. Epub 2011 Sep 24. J Dermatol Sci. 2011. PMID: 21996312

9

Oculocutaneous albinism with TYRP1 gene mutations in a Caucasian patient.

Rooryck C, Roudaut C, Robine E, Müsebeck J, Arveiler B. Rooryck C, et al. Pigment Cell Res. 2006 Jun;19(3):239-42. doi: 10.1111/j.1600-0749.2006.00298.x. Pigment Cell Res. 2006. PMID: 16704458

10

Analysis of ocular hypopigmentation in Rab38cht/cht mice.

Brooks BP, Larson DM, Chan CC, Kjellstrom S, Smith RS, Crawford MA, Lamoreux L, Huizing M, Hess R, Jiao X, Hejtmancik JF, Maminishkis A, John SW, Bush R, Pavan WJ. Brooks BP, et al. Invest Ophthalmol Vis Sci. 2007 Sep;48(9):3905-13. doi: 10.1167/iovs.06-1464. Invest Ophthalmol Vis Sci. 2007. PMID: 17724166 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

139 results

Results by year